Literature DB >> 25428384

BRCA2-associated therapy-related acute myeloid leukemia.

Armin Rashidi1, Ina Amarillo, Stephen I Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25428384     DOI： 10.1007/s12032-014-0371-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  10 in total

1.  TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.

Authors:  M S Greenblatt; P O Chappuis; J P Bond; N Hamel; W D Foulkes
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  BRCA2 mutation and the risk of hematologic malignancy.

Authors:  Michael J Hall; Loretta Li; Peter H Wiernik; Olufunmilayo I Olopade
Journal:  Leuk Lymphoma       Date:  2006-04

3.  Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.

Authors:  D H Christiansen; M K Andersen; J Pedersen-Bjergaard
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

5.  Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences.

Authors:  A Tutt; D Bertwistle; J Valentine; A Gabriel; S Swift; G Ross; C Griffin; J Thacker; A Ashworth
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

6.  Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

Authors:  Eduard Schulz; Angelika Valentin; Peter Ulz; Christine Beham-Schmid; Karin Lind; Verena Rupp; Herwig Lackner; Albert Wölfler; Armin Zebisch; Werner Olipitz; Jochen Geigl; Andrea Berghold; Michael R Speicher; Heinz Sill
Journal:  J Med Genet       Date:  2012-05-31       Impact factor: 6.318

Review 7.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

8.  Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.

Authors:  A Scardocci; F Guidi; F D'Alo'; D Gumiero; E Fabiani; A Diruscio; M Martini; L M Larocca; M Zollino; S Hohaus; G Leone; M T Voso
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

9.  Preexisting TP53 mutation in therapy-related acute myeloid leukemia.

Authors:  Eduard Schulz; Karl Kashofer; Ellen Heitzer; Ketaki N Mhatre; Michael R Speicher; Gerald Hoefler; Heinz Sill
Journal:  Ann Hematol       Date:  2014-08-20       Impact factor: 3.673

10.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962
  10 in total
  1 in total

Review 1.  The Impact of Epigenetic Modifications in Myeloid Malignancies.

Authors:  Deirdra Venney; Adone Mohd-Sarip; Ken I Mills
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.